Advertisement

Topics

Apellis Pharmaceuticals Announces that APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration

08:16 EDT 24 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Statistically Significant Slowing of Disease Progression Seen at 12 Months Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatme...

Other Sources for this Article

Denterlein for Apellis Pharmaceuticals
Tully Nicholas, 617-482-0042 (office)
860-490-0218 (mobile)
tnicholas@denterlein.com

NEXT ARTICLE

More From BioPortfolio on "Apellis Pharmaceuticals Announces that APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...